Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABT Abbott Laboratories	$133.62 +0.2%	$131.14	$110.86 ▼ $141.23	$232.56B	0.69	5.12 million shs	4.18 million shs
AZN AstraZeneca	$73.76 +0.3%	$77.13	$61.24 ▼ $82.41	$228.76B	0.37	3.60 million shs	4.34 million shs
MRK Merck & Co., Inc.	$78.51 +1.2%	$82.53	$73.31 ▼ $114.79	$196.10B	0.37	11.94 million shs	12.20 million shs
PFE Pfizer	$23.75 +0.6%	$24.55	$20.92 ▼ $30.43	$135.03B	0.55	44.84 million shs	33.32 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABT Abbott Laboratories	0.00%	-1.91%	+0.78%	-1.81%	+18.85%
AZN AstraZeneca	0.00%	-3.30%	-7.68%	+5.55%	-4.97%
MRK Merck & Co., Inc.	0.00%	-3.56%	-6.68%	-0.86%	-30.94%
PFE Pfizer	0.00%	-1.17%	-4.00%	-2.14%	-18.36%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABT Abbott Laboratories	$133.62 +0.2%	$131.14	$110.86 ▼ $141.23	$232.56B	0.69	5.12 million shs	4.18 million shs
AZN AstraZeneca	$73.76 +0.3%	$77.13	$61.24 ▼ $82.41	$228.76B	0.37	3.60 million shs	4.34 million shs
MRK Merck & Co., Inc.	$78.51 +1.2%	$82.53	$73.31 ▼ $114.79	$196.10B	0.37	11.94 million shs	12.20 million shs
PFE Pfizer	$23.75 +0.6%	$24.55	$20.92 ▼ $30.43	$135.03B	0.55	44.84 million shs	33.32 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABT Abbott Laboratories	0.00%	-1.91%	+0.78%	-1.81%	+18.85%
AZN AstraZeneca	0.00%	-3.30%	-7.68%	+5.55%	-4.97%
MRK Merck & Co., Inc.	0.00%	-3.56%	-6.68%	-0.86%	-30.94%
PFE Pfizer	0.00%	-1.17%	-4.00%	-2.14%	-18.36%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABT Abbott Laboratories	2.90	Moderate Buy	$145.22	8.68% Upside
AZN AstraZeneca	2.75	Moderate Buy	$86.00	16.59% Upside
MRK Merck & Co., Inc.	2.33	Hold	$106.41	35.54% Upside
PFE Pfizer	2.39	Hold	$28.12	18.39% Upside

Current Analyst Ratings Breakdown

Latest AZN, MRK, ABT, and PFE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/17/2025	MRK Merck & Co., Inc.	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$100.00 ➝ $90.00
8/6/2025	PFE Pfizer	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$25.00 ➝ $26.00
8/6/2025	PFE Pfizer	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$32.00 ➝ $33.00
8/6/2025	PFE Pfizer	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$27.00 ➝ $28.00
7/30/2025	MRK Merck & Co., Inc.	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Equal Weight	$97.00 ➝ $90.00
7/18/2025	ABT Abbott Laboratories	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$147.00 ➝ $142.00
7/18/2025	ABT Abbott Laboratories	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$142.00 ➝ $141.00
7/18/2025	ABT Abbott Laboratories	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$148.00 ➝ $145.00
7/18/2025	ABT Abbott Laboratories	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Buy	$143.00 ➝ $145.00
7/17/2025	ABT Abbott Laboratories	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/16/2025	ABT Abbott Laboratories	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$130.00 ➝ $140.00

(Data available from 9/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABT Abbott Laboratories	$41.95B	5.54	$6.59 per share	20.29	$27.62 per share	4.84
AZN AstraZeneca	$54.07B	4.23	$6.29 per share	11.72	$13.18 per share	5.60
MRK Merck & Co., Inc.	$64.17B	3.06	$9.46 per share	8.30	$18.33 per share	4.28
PFE Pfizer	$63.63B	2.12	$4.37 per share	5.44	$15.62 per share	1.52

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABT Abbott Laboratories	$13.40B	$7.98	16.74	23.32	2.53	32.43%	18.32%	10.71%	10/15/2025 (Estimated)
AZN AstraZeneca	$7.04B	$2.66	27.73	14.75	1.36	14.68%	32.84%	12.87%	11/11/2025 (Estimated)
MRK Merck & Co., Inc.	$17.12B	$6.49	12.10	7.93	0.81	25.79%	41.05%	16.55%	10/30/2025 (Estimated)
PFE Pfizer	$8.03B	$1.88	12.63	7.84	0.77	16.84%	21.42%	9.12%	11/4/2025 (Estimated)

Latest AZN, MRK, ABT, and PFE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
10/15/2025	Q3 2025	ABT Abbott Laboratories	$1.30	N/A	N/A	N/A	$11.40 billion	N/A
8/5/2025	Q2 2025	PFE Pfizer	$0.58	$0.78	+$0.20	$0.51	$13.43 billion	$14.65 billion
7/29/2025	Q2 2025	AZN AstraZeneca	$1.09	$1.09	N/A	$0.79	$14.08 billion	$14.46 billion
7/29/2025	Q2 2025	MRK Merck & Co., Inc.	$2.03	$2.13	+$0.10	$1.76	$15.92 billion	$15.81 billion
7/17/2025	Q2 2025	ABT Abbott Laboratories	$1.26	$1.26	N/A	$1.01	$11.01 billion	$11.14 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABT Abbott Laboratories	$2.36	1.77%	N/A	29.57%	54 Years
AZN AstraZeneca	$1.01	1.37%	N/A	37.97%	N/A
MRK Merck & Co., Inc.	$3.24	4.13%	N/A	49.92%	14 Years
PFE Pfizer	$1.72	7.24%	N/A	91.49%	16 Years

Latest AZN, MRK, ABT, and PFE Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
9/19/2025	ABT Abbott Laboratories	quarterly	$0.59	1.76%	10/15/2025	10/15/2025	11/17/2025
7/22/2025	MRK Merck & Co., Inc.	quarterly	$0.81	4%	9/15/2025	9/15/2025	10/7/2025
7/29/2025	AZN AstraZeneca	semi-annual	$0.5050	2%	8/8/2025	8/8/2025	9/8/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABT Abbott Laboratories	0.25	1.82	1.30
AZN AstraZeneca	0.55	0.86	0.67
MRK Merck & Co., Inc.	0.69	1.42	1.17
PFE Pfizer	0.65	1.16	0.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABT Abbott Laboratories	75.18%
AZN AstraZeneca	20.35%
MRK Merck & Co., Inc.	76.07%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
ABT Abbott Laboratories	0.46%
AZN AstraZeneca	N/A
MRK Merck & Co., Inc.	0.09%
PFE Pfizer	0.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABT Abbott Laboratories	114,000	1.74 billion	1.73 billion	Optionable
AZN AstraZeneca	94,300	3.10 billion	N/A	Optionable
MRK Merck & Co., Inc.	75,000	2.50 billion	2.50 billion	Optionable
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable

AZN, MRK, ABT, and PFE Headlines

Recent News About These Companies

Sound Income Strategies LLC Purchases 47,116 Shares of Pfizer Inc. $PFE

1 hour ago | marketbeat.com

Moody Lynn & Lieberson LLC Sells 17,241 Shares of Pfizer Inc. $PFE

2 hours ago | marketbeat.com

Lazari Capital Management Inc. Has $1.80 Million Holdings in Pfizer Inc. $PFE

2 hours ago | marketbeat.com

3 High-Yield Dividend Stocks to Buy Now for a Lifetime of Passive Income

3 hours ago | fool.com

Pfizer (NYSE:PFE) Downgraded to Hold Rating by Wall Street Zen

5 hours ago | americanbankingnews.com

People pass the New York Stock Exchange on November 5, 2024, in New York

Asian shares trade mostly higher after Wall Street snaps its 3-day losing streak

...

September 28 at 12:21 AM | marketbeat.com

Pfizer Inc. (PFE): A Bull Case Theory

September 28 at 4:51 PM | finance.yahoo.com

Pfizer Inc. (PFE): A Bull Case Theory

September 28 at 4:50 PM | insidermonkey.com

Why Pfizer's Post-COVID Future Looks Brighter Than Ever

September 28 at 2:10 PM | fool.com

Why Pfizer's Post-COVID Future Looks Brighter Than Ever

September 28 at 1:28 PM | fool.com

BridgeBio, Up 80% This Year, Just Unveiled Promising News For Its Pfizer Rival

September 28 at 1:00 PM | investors.com

Down 55%, Should You Buy the Dip on Pfizer?

September 28 at 11:31 AM | finance.yahoo.com

Down 55%, Should You Buy the Dip on Pfizer?

September 28 at 11:30 AM | fool.com

Down 55%, Should You Buy the Dip on Pfizer?

September 28 at 10:58 AM | fool.com

Declining Stock and Decent Financials: Is The Market Wrong About Pfizer Inc. (NYSE:PFE)?

September 28 at 10:50 AM | finance.yahoo.com

Sonora Investment Management Group LLC Has $10.90 Million Stake in Pfizer Inc. $PFE

September 28 at 8:04 AM | marketbeat.com

Pfizer Inc. $PFE Shares Acquired by Fort Washington Investment Advisors Inc. OH

September 28 at 8:02 AM | marketbeat.com

Stockman Wealth Management Inc. Buys 30,849 Shares of Pfizer Inc. $PFE

September 28 at 7:53 AM | marketbeat.com

Pfizer's Bold GLP‑1 Comeback, Dividend Safe For Now

September 28 at 6:30 AM | seekingalpha.com

Kendall Capital Management Makes New $422,000 Investment in Pfizer Inc. $PFE

September 28 at 5:16 AM | marketbeat.com

Kathmere Capital Management LLC Purchases 16,724 Shares of Pfizer Inc. $PFE

September 28 at 5:02 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

AZN, MRK, ABT, and PFE Company Descriptions

Abbott Laboratories NYSE:ABT

$133.62 +0.31 (+0.23%)

Closing price 09/26/2025 03:59 PM Eastern

Extended Trading

$132.68 -0.94 (-0.71%)

As of 04:02 AM Eastern

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

AstraZeneca NASDAQ:AZN

$73.76 +0.23 (+0.31%)

Closing price 09/26/2025 04:00 PM Eastern

Extended Trading

$74.67 +0.91 (+1.23%)

As of 06:09 AM Eastern

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Merck & Co., Inc. NYSE:MRK

$78.51 +0.91 (+1.17%)

Closing price 09/26/2025 03:59 PM Eastern

Extended Trading

$78.90 +0.38 (+0.49%)

As of 06:10 AM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Pfizer NYSE:PFE

$23.75 +0.15 (+0.64%)

Closing price 09/26/2025 03:59 PM Eastern

Extended Trading

$23.82 +0.07 (+0.32%)

As of 06:13 AM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AZN, MRK, ABT, and PFE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AZN, MRK, ABT, and PFE Earnings

Compare Dividends

Latest AZN, MRK, ABT, and PFE Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AZN, MRK, ABT, and PFE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AZN, MRK, ABT, and PFE Company Descriptions

Abbott Laboratories NYSE:ABT

AstraZeneca NASDAQ:AZN

Merck & Co., Inc. NYSE:MRK

Pfizer NYSE:PFE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools